TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 70 filers reported holding TURNING POINT THERAPEUTICS I in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $9,762,000 | +18.8% | 285,757 | -2.8% | 0.00% | +33.3% |
| Q1 2022 | $8,218,000 | -45.7% | 293,928 | -25.4% | 0.00% | -25.0% |
| Q4 2021 | $15,130,000 | -52.9% | 394,223 | -4.2% | 0.00% | -60.0% |
| Q3 2021 | $32,115,000 | +16.4% | 411,415 | +16.3% | 0.01% | +25.0% |
| Q2 2021 | $27,596,000 | +44.8% | 353,704 | +75.6% | 0.01% | +33.3% |
| Q1 2021 | $19,056,000 | -20.5% | 201,451 | +2.4% | 0.01% | -25.0% |
| Q4 2020 | $23,960,000 | +45.2% | 196,635 | +4.1% | 0.01% | +33.3% |
| Q3 2020 | $16,502,000 | +60.3% | 188,899 | +18.5% | 0.01% | +50.0% |
| Q2 2020 | $10,293,000 | +90.7% | 159,355 | +31.8% | 0.00% | +33.3% |
| Q1 2020 | $5,397,000 | -20.2% | 120,861 | +11.2% | 0.00% | 0.0% |
| Q4 2019 | $6,767,000 | +984.5% | 108,643 | +554.2% | 0.00% | – |
| Q3 2019 | $624,000 | -7.7% | 16,608 | 0.0% | 0.00% | – |
| Q2 2019 | $676,000 | – | 16,608 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 3,037,042 | $236,950,000 | 8.05% |
| MPM BioImpact LLC | 269,186 | $21,002,000 | 3.45% |
| Logos Global Management LP | 400,000 | $31,208,000 | 2.62% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 121,541 | $9,481,000 | 2.50% |
| Orbimed Advisors | 2,361,327 | $184,231,000 | 1.86% |
| First Light Asset Management, LLC | 395,825 | $30,882,000 | 1.85% |
| SECTORAL ASSET MANAGEMENT INC | 211,650 | $16,513,000 | 1.34% |
| Nicholas Investment Partners, LP | 224,876 | $17,545,000 | 1.10% |
| DAFNA Capital Management LLC | 47,852 | $3,733,000 | 0.78% |
| Eventide Asset Management | 578,000 | $45,096,000 | 0.61% |